Business Daily from THE HINDU group of publications
Thursday, Jun 12, 2008
ePaper | Mobile/PDA Version | Audio
Business Daily from THE HINDU group of publications Thursday, Jun 12, 2008 ePaper | Mobile/PDA Version | Audio |
|
|
|
|
|
|
|
Corporate
-
Outlook
Our Bureau Hyderabad, June 11 Jupiter Biosciences Ltd (JBL), the Hyderabad-based mid-sized pharma company, feels the strategic buy of Ranbaxy’s promoter’s stake by Daiichi Sankyo would give a push to its own efforts to enter the Japanese market with its peptide offerings. Jupiter Biosciences had divested 14.9 per cent stake to Ranbaxy last year and entered into a 10 year marketing tie-up for its pipeline of peptide based products, said Mr Venkat Kalavakolanu, its Chairman and Managing Director. “For us it will be a good association, since we are trying to enter the tough, regulated Japanese market. The development would be a natural fit for our peptides and chiral intermediates,” he told Business Line. Ranbaxy had picked up stake in the company with an eye on the latter’s peptide pipeline, which it expected to yield good returns after 4-5 years. Daiichi is strong both in innovation and generics and hence, for a research-driven company like ours, it augurs well, he said. “For the next one year we will deal with Ranbaxy. Normally till the merger or acquisition process is completed not much change in relationships are expected,” Mr Venkat said. More Stories on : Outlook | Mergers & Acquisitions | Pharmaceuticals | Ranbaxy Laboratories Ltd
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
 |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2008, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|